Time to platelet response
| Variable . | Total (n = 138) . | Statistical significance (P value) . |
|---|---|---|
| No. of days to platelet response, median (IQR) | 11 (7-21) | |
| No. of days to platelet response stratified by variables | ||
| Age (<65 y vs ≥65 y), d | 16.1 vs 18.7 | .531 |
| Sex (men vs women), d | 17.7 vs 18.2 | .921 |
| Baseline platelet count (<20 × 109/L vs ≥20 × 109/L), d | 18.1 vs 17.7 | .937 |
| Prior therapy with IVIG (yes/no), d | 17.8 vs 17.9 | .981 |
| Prior therapy with TPO-RAs (yes/no), d | 18.4 vs 17.0 | .514 |
| Prior therapy with rituximab (yes/no), d | 32.0 vs 12.8 | .000 |
| Splenectomized vs nonsplenectomized, d | 13.2 vs 18.5 | .370 |
| Bleeding at diagnosis (yes/no) | 19.0 vs 15.0 | .431 |
| Charlson comorbidity index at diagnosis (0 vs ≥1), d | 18.4 vs 17.1 | .752 |
| Fostamatinib received in first/second line vs third line or later, d | 14.0 vs 18.2 | .538 |
| Fostamatinib use in primary ITP vs secondary ITP, d | 17.6 vs 19.5 | .786 |
| Fostamatinib monotherapy vs use in combination, d | 15.0 vs 22.4 | .076 |
| Platelet count at fostamatinib initiation (<20 × 109/L vs ≥20 × 109/L), d | 20.8 vs 14.7 | .128 |
| Fostamatinib use in chronic ITP vs nonchronic ITP, d | 19.0 vs 16.7 | .877 |
| Variable . | Total (n = 138) . | Statistical significance (P value) . |
|---|---|---|
| No. of days to platelet response, median (IQR) | 11 (7-21) | |
| No. of days to platelet response stratified by variables | ||
| Age (<65 y vs ≥65 y), d | 16.1 vs 18.7 | .531 |
| Sex (men vs women), d | 17.7 vs 18.2 | .921 |
| Baseline platelet count (<20 × 109/L vs ≥20 × 109/L), d | 18.1 vs 17.7 | .937 |
| Prior therapy with IVIG (yes/no), d | 17.8 vs 17.9 | .981 |
| Prior therapy with TPO-RAs (yes/no), d | 18.4 vs 17.0 | .514 |
| Prior therapy with rituximab (yes/no), d | 32.0 vs 12.8 | .000 |
| Splenectomized vs nonsplenectomized, d | 13.2 vs 18.5 | .370 |
| Bleeding at diagnosis (yes/no) | 19.0 vs 15.0 | .431 |
| Charlson comorbidity index at diagnosis (0 vs ≥1), d | 18.4 vs 17.1 | .752 |
| Fostamatinib received in first/second line vs third line or later, d | 14.0 vs 18.2 | .538 |
| Fostamatinib use in primary ITP vs secondary ITP, d | 17.6 vs 19.5 | .786 |
| Fostamatinib monotherapy vs use in combination, d | 15.0 vs 22.4 | .076 |
| Platelet count at fostamatinib initiation (<20 × 109/L vs ≥20 × 109/L), d | 20.8 vs 14.7 | .128 |
| Fostamatinib use in chronic ITP vs nonchronic ITP, d | 19.0 vs 16.7 | .877 |
Variables with statistically significant differences or with a tendency to be statistically significant are indicated in bold.